This activity is supported by educational grants provided by Sanofi Genzyme and Regeneron Pharmaceuticals; and Pfizer.
This activity is part of the curriculum of the National Eczema Association's (NEA) Coalition United for Better Eczema Care (CUBE-C). The CUBE-C Initiative is designed to help providers usher in a new era of patient-centric care. In this activity, Dr. Doghramji, a family practice expert, leads a panel of Atopic Dermatitis (AD) experts and an adult patient with AD as they discuss the issues of diagnosis, treatment and management in the primary care setting. Special emphasis is placed on the importance of therapeutic patient education and the benefits of engaging patients in treatment choice.
Dermatologists, allergists, pediatricians, primary care providers, nurse practitioners, physician assistants, and other healthcare providers involved in the diagnosis, management, and treatment of patients with atopic dermatitis (AD).
At the conclusion of this educational activity, participants should be able to:
Describe the clinical features of AD and distinguish it from other eczematous eruptions
Explain the pathogenesis and consequence of epidermal skin barrier defects
Recognize the allergic and non-allergic comorbidities of AD, including psychosocial comorbidities
Assess the role of bathing and moisturizing in improving the skin barrier defects in AD patients
Assess the benefits and risks of topical therapies for treating AD, including topical calcineurin inhibitors, anti-inflammatory ointments, antibiotics, and antihistamines
Restate the general recommendations for the use of topical corticosteroids in the management of AD
Contrast the mechanisms of action of emerging therapeutic approaches for the prevention and pharmaceutical management of AD
Recognize the value of integrating patient and caregiver education into routine practice
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Lawrence F. Eichenfield, MD Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology Chief, Pediatric and Adolescent Dermatology University of California, San Diego School of Medicine
Dr. Eichenfield discloses the following: Consultant/Independent Contractor: Allergan, Anacor/Pfizer, DS Biopharma, Galderma Labs, Genentech, Lilly, Otsuka/Medimetriks, Ralaxar, Regeneron/Sanofi, TopMD, and Valeant Investigator: Regeneron/Sanofi Advisory Board: Valeant Speaker’s Bureau: Valeant
Jonathan Spergel, MD, PhD Professor of Pediatrics Perelman School of Medicine at University of Pennsylvania Chief, Allergy Section The Children’s Hospital of Philadelphia Philadelphia, PA
Dr. Spergel discloses the following: Consultant/Independent Contractor: DBV Technology and Dannone Grant/Research Support: All payable to institution-NIH, FARE, AImmune Speaker’s Bureau: MEI Stock Shareholder: DBV Technology Other/Royalty: Royalty-Uptodate
Paul Doghramji, MD, FAAFP Senior Family Physician Collegeville Family Practice Medical Director Ursinus College Collegeville, PA
Dr. Doghramji has nothing to disclose.
Jenene Chesbrough Patient Brooklyn, NY
Accredited Provider Discosures
The planners and managers involved in the planning and content of this CME activity have no financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and FACTORx. This activity is in collaboration with National Eczema Association. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and FACTORx do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.